Where trusted healthcare meets precision genetic medicine for patients with cancer. We are dedicated to providing every patients with safe, reliable and high-quality clinical genetics services to support effective cancer treatment. With a team of caring professionals and a patient-first approach, GEEN is committed to delivering accessible genetic healthcare you can depend on, every day.
2021 – The landmark INTERCEPT trial with the Mayo Clinic published in JAMA Oncology, co-authored by Dr. Esplin, demonstrated the importance of universal genetic testing for all patients with cancer to guide optimal treatment and access to clinical treatment trials.
2022 – A team of cancer experts from across the country, led by Dr. Esplin, publish the paper “Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer” in the Journal of Clinical Oncology-Precision Oncology, calling for universal genetic testing in patients with cancer.
2023 – Nationwide study by Stanford University published in the Journal of the American Medical Association (JAMA) titled “Germline Genetic Testing After Cancer Diagnosis“, co-authored by Dr. Esplin, found that >90% of patients with cancer do not receive genetic testing to guide their treatment, despite multiple FDA-approved precision cancer therapies requiring genetic testing prior to being prescribed to patients with cancer.
2023 – Drs. Atwal and Esplin meet at the American College of Medical Genetics and Genomics (ACMG) meeting in Salt Lake City, Utah to discuss the critical lack of patient access to clinical genetics services and diagnostic genetic testing, and the missed opportunity this represents for patients to receive the full benefits of precision medical therapies for genetic conditions including cancer.
2024 – Multiple clinical trials, co-authored by Dr. Esplin, show that genetic testing results positively impact the overall health outcomes of patients with breast and prostate cancer and increase the overall of survival of patients with pancreatic cancer.
2025 – At the ACMG meeting in Los Angeles, California, Drs. Esplin and Atwal decide to launch GEEN to provide virtual, AI-supported clinical genetic testing services across the country for patients with cancer, to improve patient access to, and accelerate the implementation of precision oncology therapy and amplify its positive impact on patient overall survival.
GEEN is a gene therapeutics services company whose mission is to bring genomic therapeutics, prevention and diagnostics into mainstream medicine, accelerate implementation of precision medicine and improve the health of millions of patients with cancer.
We are committed to the highest quality of service in all that we do while exceeding the expectations of those we serve.
We strive to be the clinic services provider of choice for clients, physicians, and employees.
Our clinic services shall be a valued contributor to the communities we serve and endeavor to be professional and compassionate in all of our interactions.
We shall be honest, responsible, and ethical in all our services. At all times guided by corporate values that emphasize dignity and respect for all.
MD, FACMG, FRCP(UK), FRCP(Glasg)
MD, PhD, FACMG, CGAF, FACP
[kivicareRegisterLogin]
